Synthetic Lethality in Cancer Therapeutics: The Next Generation.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
07 2021
Historique:
received: 16 10 2020
revised: 01 01 2021
accepted: 23 02 2021
pubmed: 3 4 2021
medline: 1 3 2022
entrez: 2 4 2021
Statut: ppublish

Résumé

Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not classically "druggable," including loss-of-function mutations in tumor suppressor genes required for carcinogenesis. Recent technological advances have led to an inflection point in our understanding of genetic interaction networks and ability to identify a wide array of novel SL drug targets. Here, we review concepts and lessons emerging from first-generation trials aimed at testing SL drugs, discuss how the nature of the targeted lesion can influence therapeutic outcomes, and highlight the need to develop clinical biomarkers distinct from those based on the paradigms developed to target activated oncogenes. SIGNIFICANCE: SL offers an approach for the targeting of loss of function of tumor suppressor and DNA repair genes, as well as of amplification and/or overexpression of genes that cannot be targeted directly. A next generation of tumor-specific alterations targetable through SL has emerged from high-throughput CRISPR technology, heralding not only new opportunities for drug development, but also important challenges in the development of optimal predictive biomarkers.

Identifiants

pubmed: 33795234
pii: 2159-8290.CD-20-1503
doi: 10.1158/2159-8290.CD-20-1503
pmc: PMC8295179
mid: NIHMS1680455
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1626-1635

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Science. 1997 Nov 7;278(5340):1064-8
pubmed: 9353181
Clin Cancer Res. 2010 Dec 15;16(24):6159-68
pubmed: 20802015
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Nat Commun. 2021 Mar 12;12(1):1661
pubmed: 33712601
Clin Cancer Res. 2019 Oct 15;25(20):6243-6259
pubmed: 31375513
N Engl J Med. 2020 Dec 10;383(24):2345-2357
pubmed: 32955174
Ann Oncol. 2018 May 1;29(5):1203-1210
pubmed: 29635390
Open Biol. 2019 Sep 27;9(9):190156
pubmed: 31506018
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Nature. 2007 Feb 8;445(7128):661-5
pubmed: 17251932
Nat Methods. 2017 Mar;14(3):297-301
pubmed: 28099430
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720
pubmed: 28765325
J Natl Cancer Inst. 1998 Apr 15;90(8):581-7
pubmed: 9554440
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Expert Rev Mol Diagn. 2015;15(9):1111-6
pubmed: 26292709
Leukemia. 2020 Mar;34(3):771-786
pubmed: 31690822
Nat Biotechnol. 2020 Aug;38(8):954-961
pubmed: 32231336
Cancer Discov. 2021 Jan;11(1):80-91
pubmed: 32988960
Nat Commun. 2014 Nov 17;5:5496
pubmed: 25400221
Nat Biotechnol. 2001 Oct;19(10):940-5
pubmed: 11581659
Cell. 1992 Nov 13;71(4):587-97
pubmed: 1423616
Oncogene. 2019 Apr;38(14):2451-2463
pubmed: 30532030
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Nat Rev Drug Discov. 2020 Jan;19(1):23-38
pubmed: 31712683
Genome Biol. 2020 Oct 15;21(1):262
pubmed: 33059726
Nature. 2020 Apr;580(7801):136-141
pubmed: 32238925
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Nature. 2018 Jul;559(7713):285-289
pubmed: 29973717
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Science. 2015 Nov 27;350(6264):1092-6
pubmed: 26472760
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5564-9
pubmed: 23509290
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18424-18430
pubmed: 32690674
Nat Commun. 2017 Sep 13;8(1):525
pubmed: 28904335
Nat Rev Clin Oncol. 2019 Dec;16(12):725-726
pubmed: 31582817
Nat Commun. 2016 Oct 25;7:13241
pubmed: 27779185
Nat Commun. 2019 Dec 20;10(1):5817
pubmed: 31862961
Cell. 2019 Aug 22;178(5):1189-1204.e23
pubmed: 31442407
Cancer Discov. 2019 Feb;9(2):248-263
pubmed: 30373917
Cancer Cell. 2019 Jul 8;36(1):100-114.e25
pubmed: 31257072
Nat Biotechnol. 2020 Jul;38(7):824-844
pubmed: 32572269
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Nature. 2012 Aug 16;488(7411):337-42
pubmed: 22895339
Oncotarget. 2018 May 25;9(40):25842-25859
pubmed: 29899826
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
J Pathol. 2017 Jun;242(2):165-177
pubmed: 28299801
Nature. 2019 Apr;568(7753):551-556
pubmed: 30971823
Cancer Discov. 2017 Jul;7(7):675-693
pubmed: 28630051
Cancer Res. 2001 Jun 15;61(12):4842-50
pubmed: 11406561
Sci Adv. 2020 Jan 29;6(5):eaay2611
pubmed: 32064343
Biochim Biophys Acta. 2004 Jun 7;1654(2):105-22
pubmed: 15172699
Dev Biol. 2016 Dec 15;420(2):271-277
pubmed: 27983963
Cell. 2011 Apr 1;145(1):30-8
pubmed: 21458666
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Adv Med Biol. 2017 1st Quarter;118:83-122
pubmed: 28680740
Nat Rev Genet. 2020 Nov;21(11):671-682
pubmed: 32561862
Nat Med. 2017 Jan;23(1):60-68
pubmed: 27869803
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Cancer Discov. 2019 Feb;9(2):230-247
pubmed: 30373918
Cancer Discov. 2020 Dec;10(12):1950-1967
pubmed: 32727735
Cell. 2015 Jun 18;161(7):1539-1552
pubmed: 26091037
Trends Cancer. 2015 Nov 1;1(3):161-173
pubmed: 26870836
Nat Methods. 2017 Jun;14(6):629-635
pubmed: 28417999
Nat Commun. 2020 Feb 6;11(1):752
pubmed: 32029722
Sci Rep. 2017 Dec 18;7(1):17693
pubmed: 29255251
Mol Cell. 2020 Jun 18;78(6):1152-1165.e8
pubmed: 32516598
Cancer Cell. 2020 Jul 13;38(1):31-43
pubmed: 32442401
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
JCO Precis Oncol. 2020;4:442-465
pubmed: 32903788
Clin Cancer Res. 2018 Sep 15;24(18):4482-4493
pubmed: 29858219
Cell. 2015 Dec 3;163(6):1515-26
pubmed: 26627737
Oncogene. 2006 Sep 25;25(43):5885-97
pubmed: 16998503
Cell. 2013 Nov 7;155(4):858-68
pubmed: 24209623
Mol Cell. 2019 Mar 7;73(5):885-899.e6
pubmed: 30686591
Cancer Cell. 2017 Aug 14;32(2):155-168.e6
pubmed: 28756993
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Cancer Discov. 2020 Oct;10(10):1475-1488
pubmed: 32699032
Future Oncol. 2016 Jun;12(12):1439-56
pubmed: 27087632
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nature. 2020 Oct;586(7827):120-126
pubmed: 32968282
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Adv Radiat Oncol. 2018 Oct 23;3(4):527-533
pubmed: 30370352
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Nat Med. 1996 May;2(5):561-6
pubmed: 8616716
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756
pubmed: 29078326
Clin Cancer Res. 2020 Oct 15;26(20):5462-5476
pubmed: 32816949
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
Curr Top Microbiol Immunol. 1988;141:282-9
pubmed: 3063445
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Biotechnol. 2018 Feb;36(2):179-189
pubmed: 29251726
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034
pubmed: 29506079
Nature. 2008 Feb 28;451(7182):1116-20
pubmed: 18264087
Cold Spring Harb Perspect Biol. 2019 Aug 1;11(8):
pubmed: 31371352
Mol Cell. 1999 Aug;4(2):199-207
pubmed: 10488335
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Nat Commun. 2017 Oct 11;8(1):857
pubmed: 29021619
Cell. 2020 Jul 23;182(2):481-496.e21
pubmed: 32649862
Genome Biol. 2020 Aug 19;21(1):204
pubmed: 32811551
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Cell. 2006 Dec 29;127(7):1323-34
pubmed: 17182091
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Nat Biotechnol. 2017 May;35(5):463-474
pubmed: 28319085
Nat Rev Clin Oncol. 2019 Feb;16(2):81-104
pubmed: 30356138
Genes Dev. 2001 Dec 15;15(24):3249-62
pubmed: 11751631
Cell Stem Cell. 2020 Mar 5;26(3):431-440.e8
pubmed: 32142663
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Nature. 2020 Jun;582(7812):416-420
pubmed: 32499641
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110

Auteurs

Jeremy Setton (J)

Memorial Sloan Kettering Cancer Center, New York, New York.

Michael Zinda (M)

Repare Therapeutics, Cambridge, Massachusetts.

Nadeem Riaz (N)

Memorial Sloan Kettering Cancer Center, New York, New York.

Daniel Durocher (D)

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Michal Zimmermann (M)

Repare Therapeutics, St-Laurent, Quebec, Canada.

Maria Koehler (M)

Repare Therapeutics, Cambridge, Massachusetts.

Jorge S Reis-Filho (JS)

Memorial Sloan Kettering Cancer Center, New York, New York.

Simon N Powell (SN)

Memorial Sloan Kettering Cancer Center, New York, New York. powells@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH